Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Cash from Financing Activities (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Cash from Financing Activities for 4 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities fell 97.07% year-over-year to $1.0 million, compared with a TTM value of $15.8 million through Sep 2025, down 74.19%, and an annual FY2024 reading of $59.3 million, up 2849.35% over the prior year.
  • Cash from Financing Activities was $1.0 million for Q3 2025 at Atara Biotherapeutics, down from $15.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $35.8 million in Q3 2024 and bottomed at -$328000.0 in Q4 2024.
  • Average Cash from Financing Activities over 4 years is $8.7 million, with a median of $1.0 million recorded in 2025.
  • Peak annual rise in Cash from Financing Activities hit 17308.17% in 2024, while the deepest fall reached 168.79% in 2024.
  • Year by year, Cash from Financing Activities stood at $32.3 million in 2022, then plummeted by 95.32% to $1.5 million in 2023, then tumbled by 121.69% to -$328000.0 in 2024, then surged by 419.21% to $1.0 million in 2025.
  • Business Quant data shows Cash from Financing Activities for ATRA at $1.0 million in Q3 2025, $15.3 million in Q2 2025, and -$250000.0 in Q1 2025.